Results 131 to 140 of about 15,279 (220)

Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey.

Lancet Glob Health, 2023
Kennedy SB, Macklin GR, Mason Ross G, Lopez Cavestany R, Moukom RA, Jones KAV, Mainou BA, Massaquoi MBF, Kieh MWS, Mach O.   +9 more
europepmc   +1 more source

Notes from the Field: Readiness for Use of Type 2 Novel Oral Poliovirus Vaccine in Response to a Type 2 Circulating Vaccine-Derived Poliovirus Outbreak - Tajikistan, 2020-2021. [PDF]

MMWR Morb Mortal Wkly Rep, 2022
O'Connor P, Huseynov S, Nielsen CF, Saidzoda F, Saxentoff E, Sadykova U, Kormoss P.   +6 more
europepmc   +1 more source

Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. [PDF]

Vaccine X, 2021
Konz JO, Schofield T, Carlyle S, Wahid R, Ansari A, Strating JRPM, Yeh MT, Manukyan H, Smits SL, Tritama E, Rahmah L, Ugiyadi D, Andino R, Laassri M, Chumakov K, Macadam A.   +15 more
europepmc   +1 more source

Assessment of Oral Poliovirus Vaccine Viability and Titer at Delivery Points in Kinshasa, the Democratic Republic of the Congo: Implications for Cold Chain Management. [PDF]

Vaccines (Basel)
Kashitu-Mujinga G, Makaka-Mutondo A, Matondo-Kuamfumu M, Mambu-Mbika F, Bulabula-Penge J, Kabeya-Mampuela T, Nkawa F, Wanet-Tayele G, Nsunda-Makanzu B, Nsele-Muntatu P, Kabamba L, Nkuba-Ndaye A, Cikomola AMWB, Mukamba-Musenga E, Ahuka-Mundeke S.   +14 more
europepmc   +1 more source

Post-vaccination campaign evaluation of systemic and mucosal immunity of trivalent oral poliovirus vaccine in Karachi, Pakistan (2020-2021): a cross-sectional study. [PDF]

Lancet Reg Health Southeast Asia
Saleem AF, Jeyaseelan V, Kazi Z, Zehra M, Alam MM, Macklin G, Cavestany RL, Muhammad S, Rehman N, Mach O.   +9 more
europepmc   +1 more source

Use of killed poliovirus vaccine in a routine immunization program in West Africa [PDF]

, 1984
Evans, A., Maire, Bernard, Parent, Gérard, Salk, D., Schlumberger, M., Stoeckel, P., Van Steenis, G., Van Wezel, A.   +7 more
core   +1 more source

Optimal Disease Eradication [PDF]

Using a dynamic model of the control of an infectious disease, we derive the conditions under which eradication will be optimal. When eradication is feasible, the optimal program requires either a low vaccination rate or eradication.
Michael Hoel, Scott Barrett
core  

Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV). [PDF]

Pathogens
Badizadegan ND, Wassilak SGF, Estívariz CF, Wiesen E, Burns CC, Bolu O, Thompson KM.   +6 more
europepmc   +1 more source

Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine. [PDF]

BMC Infect Dis
Xu J, Liu Y, Qiu W, Li W, Hu X, Li X, Fan Q, Tang W, Wang Y, Wang Q, Yao N.   +10 more
europepmc   +1 more source

Analysis of vaccination campaign effectiveness and population immunity to support and sustain polio elimination in Nigeria [PDF]

, 2016

core   +1 more source